Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture

AIDS Research and Therapy

Volumn 6, Issue , 2009, Pages

  Paintsil, Elijah ^a   Grill, Susan P ^a   Dutschman, Ginger E ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; ELVUCITABINE; EMTRICITABINE; FESTINAVIR; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL PROTECTION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REBOUND;

EID: 66349096006     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-6-5     Document Type: Article

References (49)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2008, 1-128 http://aidsinfo.nih.gov/Guidelines
2. Kakuda TN Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity Clin Ther 2000, 22:685-708 10.1016/S0149-2918(00)90004-3 10929917
3. Back D Gatti G Fletcher C Garaffo R Haubrich R Hoetelmans R Kurowski M Luber A Merry C Perno CF Therapeutic drug monitoring in HIV infection: current status and future directions AIDS 2002, 16(Suppl 1):S5-37 10.1097/00002030-200203001-00002 12035820
4. Gerber JG Acosta EP Therapeutic drug monitoring in the treatment of HIV-infection J Clin Virol 2003, 27:117-128 10.1016/ S1386-6532(03)00033-7 12829033
5. Spenlehauer C Gordon CA Trkola A Moore JP A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1 Virology 2001, 280:292-300 10.1006/ viro.2000.0780 11162843
6. Hachiya A Aizawa-Matsuoka S Tanaka M Takahashi Y Ida S Gatanaga H Hirabayashi Y Kojima A Tasumi M Oka S Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5) Antimicrob Agents Chemother 2001, 45:495-501 90318 11158746 10.1128/AAC.45.2.495-501.2001
7. Gervaix A West D Leoni LM Richman DD Wong-Staal F Corbeil J A new reporter cell line to monitor HIV infection and drug susceptibility in vitro Proc Natl Acad Sci USA 1997, 94:4653-4658 20779 9114046 10.1073/ pnas.94.9.4653
8. Chiba-Mizutani T Miura H Matsuda M Matsuda Z Yokomaku Y Miyauchi K Nishizawa M Yamamoto N Sugiura W Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs J Clin Microbiol 2007, 45:477-487 1829063 17182760 10.1128/JCM.01708-06
9. Ferguson NM Fraser C Anderson RM Viral dynamics and anti-viral pharmacodynamics: Rethinking in vitro measures of drug potency Trends Pharmacol Sci 2001, 22:97-100 10.1016/S0165-6147(00)01615-1 11166854
10. Shen L Peterson S Sedaghat AR McMahon MA Callender M Zhang H Zhou Y Pitt E Anderson KS Acosta EP Siliciano RF Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs Nat Med 2008, 14:762-766 10.1038/nm1777 18552857
11. Paintsil E Dutschman GE Hu R Grill SP Lam W Baba M Tanaka H Cheng YC Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine, a novel thymidine analog Antimicrob Agents Chemother 2007, 51:3870-3879 2151449 17724147 10.1128/AAC.00692-07
12. Wei X Decker JM Liu H Zhang Z Arani RB Kilby JM Saag MS Wu X Shaw GM Kappes JC Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy Antimicrob Agents Chemother 2002, 46:1896-1905 127242 12019106 10.1128/ AAC.46.6.1896-1905.2002
13. Dutschman GE Grill SP Gullen EA Haraguchi K Takeda S Tanaka H Baba M Cheng YC Novel 4′-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity Antimicrob Agents Chemother 2004, 48:1640-1646 400579 15105115 10.1128/ AAC.48.5.1640-1646.2004
14. Haraguchi K Takeda S Tanaka H Nitanda T Baba M Dutschman GE Cheng YC Synthesis of a highly active new anti-HIV agent 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine Bioorg Med Chem Lett 2003, 13:3775-3777 10.1016/j.bmcl.2003.07.009 14552777
15. Waheed AA Ablan SD Mankowski MK Cummins JE Ptak RG Schaffner CP Freed EO Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants J Biol Chem 2006, 281:28699-28711 10.1074/jbc.M603609200 16882663
16. Lin TS Luo MZ Liu MC Zhu YL Gullen E Dutschman GE Cheng YC Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro- beta-L-cytidine (beta-L-d4C) and 2′,3′-dideoxy 2′,3′-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro J Med Chem 1996, 39:1757-1759 10.1021/jm950836q 8627596
17. Dutschman GE Bridges EG Liu SH Gullen E Guo X Kukhanova M Cheng YC Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-beta- L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrob Agents Chemother 1998, 42:1799-1804
18. Bridges EG Dutschman GE Gullen EA Cheng YC Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus Biochem Pharmacol 1996, 51:731-736 10.1016/0006-2952(96)00056-1 8602867
19. Witvrouw M Pannecouque C Desmyter J De Clercq E Andries K In vitro evaluation of the effect of temporary removal of HIV drug pressure Antiviral Res 2000, 46:215-221 10.1016/S0166-3542(00)00084-X 10867159
20. Moore KH Barrett JE Shaw S Pakes GE Churchus R Kapoor A Lloyd J Barry MG Back D The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1 AIDS 1999, 13:2239-2250 10.1097/00002030-199911120-00006 10563709
21. Podsadecki TJ Vrijens BC Tousset EP Rode RA Hanna GJ Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia J Infect Dis 2007, 196:1773-1778 10.1086/523704 18190257
22. Gardner EM Sharma S Peng G Hullsiek KH Burman WJ Macarthur RD Chesney M Telzak EE Friedland G Mannheimer SB Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance AIDS 2008, 22:75-82 2405889 18090394 10.1097/ QAD.0b013e3282f366ff
23. Balzarini J Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives Pharm World Sci 1994, 16:113-126 10.1007/ BF01880662 8032337
24. Meyerhans A Vartanian JP Hultgren C Plikat U Karlsson A Wang L Erikson S Wain-Hobson S Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools J Virol 1994, 68:535-540 236318 8254768
25. Back NK Nijhuis M Keulen W Boucher CA Oude Essink BO van Kuilenburg AB van Gennip AH Berkhout B Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme Embo J 1996, 15:4040-4049 452124 8670908
26. Anderson PL Kakuda TN Kawle S Fletcher CV Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals AIDS 2003, 17:2159-2168 10.1097/ 00002030-200310170-00003 14523272
27. Moyer TP Temesgen Z Enger R Estes L Charlson J Oliver L Wright A Drug Monitoring of Antiretroviral Therapy for HIV-1 Infection: Method Validation and Results of a Pilot Study Clin Chem 1999, 45:1465-1476 10471649
28. Schinazi RF Hernandez-Santiago BI Hurwitz SJ Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses Antiviral Res 2006, 71:322-334 10.1016/j.antiviral.2006.03.012 16716415
29. Mastuda T Paintsil E Ross JS Schofield J Cheng YC Urata Y A Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OBP-601 (4;-Ed4Ta Novel NRTI) in Healthy Subjects 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada 2009
30. Moore JD Acosta EP Johnson VA Bassett R Eron JJ Fischl MA Long MC Kuritzkes DR Sommadossi JP Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy Antivir Ther 2007, 12:981-986 17926654
31. Hawkins T Veikley W St Claire RL 3rd Guyer B Clark N Kearney BP Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens J Acquir Immune Defic Syndr 2005, 39:406-411 10.1097/01.qai.0000167155.44980.e8 16010161
32. Zimmerman TP Mahony WB Prus KL 3′-azido-3′-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion J Biol Chem 1987, 262:5748-5754 3471758
33. Reisler RB Murphy RL Redfield RR Parker RA Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: Lessons learned J Acquir Immune Defic Syndr 2005, 39:159-166 1373674 15905731
34. Tsai CC Emau P Follis KE Beck TW Benveniste RE Bischofberger N Lifson JD Morton WR Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment J Virol 1998, 72:4265-4273 109656 9557716
35. Bottiger D Johansson NG Samuelsson B Zhang H Putkonen P Vrang L Oberg B Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005 AIDS 1997, 11:157-162 10.1097/00002030-199702000-00004 9030361
36. Smith DK Grohskopf LA Black RJ Auerbach JD Veronese F Struble KA Cheever L Johnson M Paxton LA Onorato IM Greenberg AE Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: Recommendations from the U.S. Department of Health and Human Services MMWR Recomm Rep 2005, 54:1-20 15660015
37. Cranage M Sharpe S Herrera C Cope A Dennis M Berry N Ham C Heeney J Rezk N Kashuba A Anton P McGowan I Shattock R Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel PLoS Med 2008, 5:e157 2494562 18684007 10.1371/journal.pmed.0050157
38. Dumond JB Yeh RF Patterson KB Corbett AH Jung BH Rezk NL Bridges AS Stewart PW Cohen MS Kashuba AD Antiretroviral drug exposure in the female genital tract: Implications for oral pre- and post-exposure prophylaxis AIDS 2007, 21:1899-1907 10.1097/QAD.0b013e328270385a 17721097
39. Chi BH Sinkala M Mbewe F Cantrell RA Kruse G Chintu N Aldrovandi GM Stringer EM Kankasa C Safrit JT Stringer JS Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: An open-label randomised trial Lancet 2007, 370:1698-1705 10.1016/S0140-6736(07)61605-5 17997151
40. Sharkey ME Teo I Greenough T Sharova N Luzuriaga K Sullivan JL Bucy RP Kostrikis LG Haase A Veryard C Davaro RE Cheesman SH Daly JS Bova C Ellison RT 3rd Mady B Lai KK Moyle G Nelson M Gazzard B Shaunak S Stevenson M Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy Nat Med 2000, 6:76-81 10.1038/71569 10613828
41. Ramratnam B Mittler JE Zhang L Boden D Hurley A Fang F Macken CA Perelson AS Markowitz M Ho DD The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy Nat Med 2000, 6:82-85 10.1038/71577 10613829
42. Nakata H Amano M Koh Y Kodama E Yang G Bailey CM Kohgo S Hayakawa H Matsuoka M Anderson KS Cheng YC Mitsuya H Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4′-ethynyl-2-fluoro-2′-deoxyadenosine Antimicrob Agents Chemother 2007, 51:2701-2708 1932487 17548498 10.1128/AAC.00277-07
43. Bedimo R Chen RY Westfall AO Raper JL Allison JJ Saag MS Sustained HIV viral suppression following treatment interruption: An observational study AIDS Res Hum Retroviruses 2006, 22:40-44 10.1089/aid.2006.22.40 16438644
44. Eron JJ Jr Bartlett JA Santana JL Bellos NC Johnson J Keller A Kuritzkes DR St Clair MH Johnson VA Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation J Acquir Immune Defic Syndr 2004, 37:1581-1583 10.1097/00126334-200412150-00009 15577413
45. Balzarini J Karlsson A Perez-Perez MJ Camarasa MJ De Clercq E Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus Virology 1993, 196:576-585 10.1006/viro.1993.1513 7690501
46. Okamoto M Makino M Yamada K Nakade K Yuasa S Baba M Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells Antiviral Res 1996, 31:69-77 10.1016/0166-3542(96)00946-1 8793010
47. Cheeseman SH Hattox SE McLaughlin MM Pharmacokinetics of nevirapine: initial single-rising-dose study in humans Antimicrob Agents Chemother 1993, 37:178-182 187634 8452345
48. Eshleman SH Mracna M Guay LA Deseyve M Cunningham S Mirochnick M Musoke P Fleming T Glenn Fowler M Mofenson LM Mmiro F Jackson JB Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) AIDS 2001, 15:1951-1957 10.1097/00002030-200110190-00006 11600822
49. Feng JY Murakami E Zorca SM Johnson AA Johnson KA Schinazi RF Furman PA Anderson KS Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2′,3′-dideoxy-5-fluoro-3′-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase Antimicrob Agents Chemother 2004, 48:1300-1306 375312 15047533 10.1128/AAC.48.4.1300-1306.2004